MX2014015258A - Variantes del factor 21 de crecimiento de fibroblasto. - Google Patents

Variantes del factor 21 de crecimiento de fibroblasto.

Info

Publication number
MX2014015258A
MX2014015258A MX2014015258A MX2014015258A MX2014015258A MX 2014015258 A MX2014015258 A MX 2014015258A MX 2014015258 A MX2014015258 A MX 2014015258A MX 2014015258 A MX2014015258 A MX 2014015258A MX 2014015258 A MX2014015258 A MX 2014015258A
Authority
MX
Mexico
Prior art keywords
variants
growth factor
fibroblast growth
fgf21
dyslipidemia
Prior art date
Application number
MX2014015258A
Other languages
English (en)
Inventor
Ryan James Darling
Craig Duane Dickinson
David Albert Driver
Malgorzata Donata Gonciarz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2014015258A publication Critical patent/MX2014015258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a variantes del factor 21 de crecimiento de fibroblasto humano (FGF21) farmacológicamente potentes y estables, composiciones farmacéuticas que comprenden las variantes del FGF21, y métodos para tratar diabetes tipo 2, obesidad, dislipidemia, y/o síndrome metabólico usando tales variantes.
MX2014015258A 2012-06-11 2013-06-05 Variantes del factor 21 de crecimiento de fibroblasto. MX2014015258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658110P 2012-06-11 2012-06-11
PCT/US2013/044192 WO2013188182A1 (en) 2012-06-11 2013-06-05 Fibroblast growth factor 21 variants

Publications (1)

Publication Number Publication Date
MX2014015258A true MX2014015258A (es) 2015-03-05

Family

ID=48626674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015258A MX2014015258A (es) 2012-06-11 2013-06-05 Variantes del factor 21 de crecimiento de fibroblasto.

Country Status (12)

Country Link
US (1) US9422353B2 (es)
EP (1) EP2859014B1 (es)
JP (1) JP6181752B2 (es)
KR (1) KR20150006059A (es)
CN (1) CN104364261B (es)
AU (1) AU2013274639A1 (es)
CA (1) CA2871656A1 (es)
EA (1) EA201492064A1 (es)
ES (1) ES2632078T3 (es)
MX (1) MX2014015258A (es)
WO (1) WO2013188182A1 (es)
ZA (1) ZA201407938B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
US20190201491A1 (en) 2016-08-22 2019-07-04 Elanco Us Inc. Bovine fibroblast growth factor 21 and ketosis in dairy cattle
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
BR112019012693A2 (pt) 2016-12-22 2019-11-19 Sanofi combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
KR102094184B1 (ko) 2018-05-18 2020-03-27 고려대학교 산학협력단 Crtc 2의 간 특이적 조절에 의한 지방간 및 비만 제어용 조성물
EP3935075A4 (en) 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US20240165202A1 (en) * 2021-03-19 2024-05-23 Sunshine Lake Pharma Co., Ltd. Uses of fgf21 polypeptides and fusion polypeptides thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP2270163A1 (en) 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
CN101520547B (zh) * 2009-04-17 2011-05-18 东南大学 挠曲柱面反射式聚光镜制造方法
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質

Also Published As

Publication number Publication date
CN104364261A (zh) 2015-02-18
US9422353B2 (en) 2016-08-23
JP2015521596A (ja) 2015-07-30
KR20150006059A (ko) 2015-01-15
ZA201407938B (en) 2016-08-31
CN104364261B (zh) 2017-04-05
JP6181752B2 (ja) 2017-08-16
CA2871656A1 (en) 2013-12-19
EP2859014B1 (en) 2017-04-26
ES2632078T3 (es) 2017-09-08
AU2013274639A1 (en) 2014-11-06
EP2859014A1 (en) 2015-04-15
US20150141327A1 (en) 2015-05-21
WO2013188182A1 (en) 2013-12-19
EA201492064A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
PH12014502766A1 (en) Fibroblast growth factor 21 proteins
TN2014000096A1 (en) Fibroblast growth factor 21 variants
UY33739A (es) Metodos de tratamiento de trastornos asociados con el fgf21
TN2015000053A1 (en) Fusion proteins for treating a metabolic syndrome
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2015008114A (es) Derivados de exendina-4.
IN2014DN09805A (es)
MX2014015423A (es) Analogos de peptido de exedina-4.
IN2014DN09804A (es)
MX342947B (es) Tratamiento de diabetes tipo 2.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
IN2014DN09297A (es)
MX337145B (es) Composiciones farmaceuticas.
UA112981C2 (uk) Варіант людського gdnf
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders
PH12013501069A1 (en) Pharmaceutical compositions
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA93232C2 (uk) Спосіб виготовлення лікарського препарату у формі таблеток на основі міансерину гідрохлориду